Copeptin, a surrogate marker for arginine vasopressin, is associated with disease severity and progression in IgA nephropathy patients

Nephrology Dialysis Transplantation

Volumn 32, Issue , 2017, Pages I146-I153

  Zittema, Debbie ^a   van den Brand, Jan A J G ^b   Bakker, Stephan J L ^a   Wetzels, Jack F ^b   Gansevoort, Ron T ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Copeptin; IgA nephropathy; Predictor; Renal outcome

Indexed keywords

ARGIPRESSIN; BIOLOGICAL MARKER; COPEPTIN; CREATININE; GLYCOPEPTIDE;

ADULT; BLOOD; DISEASE COURSE; FEMALE; GLOMERULONEPHRITIS, IGA; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION TEST; MALE; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX;

ADULT; ARGININE VASOPRESSIN; BIOMARKERS; CREATININE; DISEASE PROGRESSION; FEMALE; GLOMERULAR FILTRATION RATE; GLOMERULONEPHRITIS, IGA; GLYCOPEPTIDES; HUMANS; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 85030614873     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfw391     Document Type: Article

References (35)

1. D'Amico G. The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med 1987; 64: 709-727
2. Berthoux F, Suzuki H, Thibaudin L et al. Autoantibodies targeting galactosedeficient IgA1 associate with progression of IgA nephropathy. J Am Soc Nephrol 2012; 23: 1579-1587
3. Waldherr R, Rambausek M, Duncker WD et al. Frequency of mesangial IgA deposits in a non-selected autopsy series. Nephrol Dial Transplant 1989; 4: 943-946
4. Suzuki K, Honda K, Tanabe K et al. Incidence of latent mesangial IgA deposition in renal allograft donors in Japan. Kidney Int 2003; 63: 2286-2294
5. Wyatt RJ, Julian BA, Baehler RW et al. Epidemiology of IgA nephropathy in central and eastern Kentucky for the period 1975 through 1994. Central Kentucky Region of the Southeastern United States IgA Nephropathy DATABANK Project. J Am Soc Nephrol 1998; 9: 853-858
6. Gellai M, Silverstein JH, Hwang JC et al. Influence of vasopressin on renal hemodynamics in conscious Brattleboro rats. Am J Physiol 1984; 246 (6 Pt 2): F819-F827
7. Bardoux P, Bichet DG, Martin H et al. Vasopressin increases urinary albumin excretion in rats and humans: involvement of V2 receptors and the renin-angiotensin system. Nephrol Dial Transplant 2003; 18: 497-506
8. Bouby N, Hassler C, Bankir L. Contribution of vasopressin to progression of chronic renal failure: study in Brattleboro rats. Life Sci 1999; 65: 991-1004
9. Preibisz JJ, Sealey JE, Laragh JH et al. Plasma and platelet vasopressin in essential hypertension and congestive heart failure. Hypertension 1983; 5 (2 Pt 2): I129-1138
10. Morgenthaler NG, Struck J, Alonso C et al. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 2006; 52: 112-119
11. Meijer E, Bakker SJ, de Jong PE et al. Copeptin, a surrogate marker of vasopressin, is associated with accelerated renal function decline in renal transplant recipients. Transplantation 2009; 88: 561-567
12. Boertien WE, Riphagen IJ, Drion I et al. Copeptin, a surrogate marker for arginine vasopressin, is associated with declining glomerular filtration in patients with diabetes mellitus (ZODIAC-33). Diabetologia 2013; 56: 1680-1688
13. Velho G, Bouby N, Hadjadj S et al. Plasma copeptin and renal outcomes in patients with type 2 diabetes and albuminuria. Diabetes Care 2013; 36: 3639-3645
14. Boertien WE, Meijer E, Zittema D et al. Copeptin, a surrogate marker for vasopressin, is associated with kidney function decline in subjects with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 2012; 27: 4131-4137
15. Boertien WE, Meijer E, Li J et al. Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP Cohort. Am J Kidney Dis 2012; 61: 420-429
16. Lacquaniti A, Chirico V, Lupica R et al. Apelin and copeptin: two opposite biomarkers associated with kidney function decline and cyst growth in autosomal dominant polycystic kidney disease. Peptides 2013; 49: 1-8
17. Branten AJ, du Buf-Vereijken PW, Klasen IS et al. Urinary excretion of beta2-microglobulin and IgG predict prognosis in idiopathic membranous nephropathy: a validation study. J Am Soc Nephrol 2005; 16: 169-174
18. Levey AS, Stevens LA, Schmid CH et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612
19. Meijer E, Bakker SJ, Halbesma N et al. Copeptin, a surrogate marker of vasopressin, is associated with microalbuminuria in a large population cohort. Kidney Int 2010; 77: 29-36
20. Bolignano D, Zoccali C. Vasopressin beyond water: implications for renal diseases. Curr Opin Nephrol Hypertens 2010; 19: 499-504
21. Aoyagi T, Koshimizu TA, Tanoue A. Vasopressin regulation of blood pressure and volume: findings from V1a receptor-deficient mice. Kidney Int 2009; 76: 1035-1039
22. Seney FD Jr, Persson EG, Wright FS. Modification of tubuloglomerular feedback signal by dietary protein. Am J Physiol 1987; 252 (1 Pt 2): F83-F90
23. Bouby N, Ahloulay M, Nsegbe E et al. Vasopressin increases glomerular filtration rate in conscious rats through its antidiuretic action. J Am Soc Nephrol 1996; 7: 842-851
24. Bankir L, Ahloulay M, Bouby N et al. Is the process of urinary urea concentration responsible for a high glomerular filtration rate? J Am Soc Nephrol 1993; 4: 1091-1103
25. Wolthuis A, Boes A, Rodemann HP et al. Vasoactive agents affect growth and protein synthesis of cultured rat mesangial cells. Kidney Int 1992; 41: 124-131
26. Bakris GL, Fairbanks R, Traish AM. Arginine vasopressin stimulates human mesangial cell production of endothelin. J Clin Invest 1991; 87: 1158-1164
27. Higashiyama M, Ishikawa S, Saito T et al. Arginine vasopressin inhibits apoptosis of rat glomerular mesangial cells via V1a receptors. Life Sci 2001; 68: 1485-1493
28. Tahara A, Tsukada J, Tomura Y et al. Effect of YM218, a nonpeptide vasopressin V(1A) receptor-selective antagonist, on rat mesangial cell hyperplasia and hypertrophy. Vascul Pharmacol 2007; 46: 463-469
29. Wang CJ, Grantham JJ, Wetmore JB. The medicinal use of water in renal disease. Kidney Int 2013; 84: 45-53
30. Bouby N, Bachmann S, Bichet D et al. Effect of water intake on the progression of chronic renal failure in the 5/6 nephrectomized rat. Am J Physiol 1990; 258 (4 Pt 2): F973-F979
31. Clark WF, Sontrop JM, Macnab JJ et al. Urine volume and change in estimated GFR in a community-based cohort study. Clin J Am Soc Nephrol 2011; 6: 2634-2641
32. Strippoli GF, Craig JC, Rochtchina E et al. Fluid and nutrient intake and risk of chronic kidney disease. Nephrology 2011; 16: 326-334
33. Clark WF, Sontrop JM, Huang SH et al. The chronic kidney disease Water Intake Trial (WIT): results from the pilot randomised controlled trial. BMJ Open 2013; 3: e003666
34. Baumann G, Dingman JF. Distribution, blood transport, and degradation of antidiuretic hormone in man. J Clin Invest 1976; 57: 1109-1116
35. Zittema D, Boertien WE, van Beek AP et al. Vasopressin, copeptin, and renal concentrating capacity in patients with autosomal dominant polycystic kidney disease without renal impairment. Clin J Am Soc Nephrol 2012; 7: 906-913